Dr. Reddy's Launches Drug-Free Migraine Management Device Nerivio In Europe Following Successful Launch In India
Dr. Reddy's Launches Drug-Free Migraine Management Device Nerivio In Europe Following Successful Launch In India
繼印度成功推出後，雷迪博士在歐洲推出了無毒偏頭痛管理設備Nerivio
Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, hereafter referred to as ", Dr. Reddy', s", )), a global pharmaceutical company, announced the launch of the drug-free non-invasive migraine management wearable device Nerivio in Germany through its step-down subsidiary betapharm. The launch marks the company's entry into digital therapeutics in Europe. Nerivio is approved by the United States Food and Drug Administration (USFDA), and is CE-mark certified in Europe.
全球製藥公司雷迪博士實驗室有限公司（BSE：500124，紐約證券交易所：DRREDDY，紐約證券交易所代碼：RDY，NSEIFSC：DRREDDY，以下簡稱 “，雷迪博士，s”，））宣佈通過其下臺子公司betapharm在德國推出無藥非侵入性偏頭痛管理可穿戴設備Nerivio。此次推出標誌着該公司進入歐洲數字療法。Nerivio 已獲得美國食品藥品監督管理局 (USFDA) 的批准，並在歐洲獲得了 CE 標誌認證。